摘要
目的 探讨组蛋白去乙酰化酶抑制剂LBH589对急性髓系白血病细胞株HL660/ADM的增殖、凋亡和耐药的影响.方法 采用不同浓度LBH589处理耐药的HL60/ADM细胞,四甲基偶氮唑蓝(MTT)法检测细胞增殖和多柔比星作用24h IC50值,AnnexinV-FITC/PI荧光染色流式细胞术检测细胞凋亡、多柔比星摄取率和多药耐药蛋白1(MRP1)表达,评估LBH589逆转耐药效应.Westemblot检测p53、Akt、p-Akt、组蛋白-3、乙酰化组蛋白-3、β-actin蛋白表达.结果 10~80 nmol/L LBH589能够抑制HL60/ADM细胞增殖和诱导凋亡,70 nmol/LLBH589作用60 h抑制效果最佳.20 nmol/LLBH589显著下调HL60/ADM细胞表面MRP1的表达[(93.90±4.20)%比(76.19±6.53)%,P<0.05]、提高HL60/ADM细胞多柔比星摄取率[(8.53±0.68)%比(25.67±1.34)%,P< 0.01]、降低多柔比星24 hIG0值[(6.833±0.319) μg/ml比(1.382±0.104)μg/ml,P< 0.01],其逆转耐药倍数为4.9倍.LBH589处理HL60/ADM细胞24、48 h,乙酰化组蛋白-3相对表达水平均高于LBH589处理前(P<0.01),处理后24h和48 h p-Akt相对表达水平分别为1.07±0.09和0.59±0.01,低于处理前表达水平(2.03±0.12)(P<0.01),p53蛋白相对表达水平分别为0.57±0.04和1.31±0.09,明显高于处理前的表达(0.21±0.02)(P< 0.01).结论 LBH589通过阻断PI3K-Akt通路、下调其MRP1的表达及提高多柔比星摄取率有效地抑制HL60/ADM细胞的增殖和诱导其凋亡,并逆转其耐药.
Objective To investigate the effect of histone deacetylase inhibitor LBH589 on proliferation,apoptosis and drug resistance of chemoresistant acute myeloid leukemia cells HL60/ADM.Methods HL60/ADM cells were treated with LBH589.Proliferation,apoptosis and adriamycin IC50 were evaluated by MTT assay and AnnexinV-FITC/PI stain.The change in MRP1 expression and intercellular adriamycin accumulatiom were analyzed by flow cytometry.Results Effective proliferative inhibition and apoptotic induction in HL60/ADM cells were observed after treatment with 10-80 nmol/L LBH589 with maximal effect detected after treatment with 70 nmol/L LBH589 for 60 hours.However,inhibition ratio remain unchanged with the further increase of drug dose and incubation time (P > 0.05).Downregulation of MRP1 [(93.90±4.20) % vs (76.19±6.53) %],upregulation of adriamycin accumulation [(8.53±0.68) % vs (25.67±1.34) %] and decrease in adriamycin IC50 [(6.833±0.319) μg/ml vs (1.382±0.104) μg/ml] were induced by the treatment with 20 nmol/L LBH589 (P < 0.01),whose reversal fold was 4.9.The expression of acetylated histone 3 after treatment with LBH589 was higher than that before treatment (P < 0.01).However,relative p-Akt levels after treatment for 24 h and 48 h were 1.07±0.09 and 0.59±0.01,respectively,which were lower than that before treatment (2.03±0.12) (P < 0.01).Meanwhile,expression levels of p53 were 0.57±0.04 and 1.31±0.09,respectively,which were higher than that before treatment (0.21 ±0.02) (P < 0.01).Conclusion Treatment with LBH589 has the capability of inhibiting proliferation and inducing apoptosis,as well as increasing intercellular adriamycin accumulation and sensitivity through downregulation of MRP1 expression and inhibition of PI3K-Akt signaling pathway in HL60/ADM cells.
出处
《白血病.淋巴瘤》
CAS
2014年第4期199-203,共5页
Journal of Leukemia & Lymphoma
关键词
白血病
组蛋白脱乙酰基酶抑制剂
细胞增殖
凋亡
抗药性
肿瘤
Leukemia
Histone deacetylase Inhibitor
Cell proliferation
Apoptosis
Drug resistance, neoplasm